Plitidepsin

Generic Name: Plitidepsin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₅₇H_₈₇N_₇O_₁₅

CAS Number: 137219-37-5

Unique Ingredient Identifier: Y76ID234HW

Background: Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatment for some leukemias.

Indication: Intended for the treatment of various forms of cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Plitidepsin

First Posted Date: 2023-01-30

Last Posted Date: 2024-12-02

Lead Sponsor: PharmaMar

Target Recruit Count: 37

Registration Number: NCT05705167

Locations: 🇮🇹
IRCCS Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma, Rome, Italy
🇧🇪
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Flemish Brabant, Belgium
🇫🇷
Centre Hospitalier de la Côte Basque, Bayonne, Pyrénées-Atlantiques, France

and more 41 locations

Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Phase 3

Terminated

Conditions: COVID-19 Infection

Interventions: Drug: Plitidepsin
Drug: Dexamethasone
Drug: Remdesivir
Drug: Favipiravir

First Posted Date: 2021-03-05

Last Posted Date: 2023-03-09

Lead Sponsor: PharmaMar

Target Recruit Count: 205

Registration Number: NCT04784559

Locations: 🇧🇷
Hospital Felicio Rocho, Belo Horizonte, MG, Brazil
🇲🇽
Universidad Autonoma de Nuevo Leon - Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, NL, Mexico
🇷🇴
Institutul National De Boli Infectioase "Prof. Dr. Matei Bals", Bucharest, Romania

and more 25 locations

Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: plitidepsin
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2017-04-17

Last Posted Date: 2020-12-02

Lead Sponsor: PharmaMar

Target Recruit Count: 10

Registration Number: NCT03117361

Locations: 🇫🇷
CHRU de Lille - Hôpital Claude Huriez, Lille, France
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇮🇹
Policlinico Vittorio Emanuele Hospital, Catania, Italy

and more 10 locations

A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: plitidepsin

First Posted Date: 2017-03-06

Last Posted Date: 2020-10-14

Lead Sponsor: PharmaMar

Target Recruit Count: 14

Registration Number: NCT03070964

Locations: 🇺🇸
Northwestern University Medical School, Chicago, Illinois, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇨🇿
Faculty Hospital Ostrava, Ostrava, Czechia

and more 14 locations

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Plitidepsin
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2014-04-01

Last Posted Date: 2020-10-12

Lead Sponsor: PharmaMar

Target Recruit Count: 39

Registration Number: NCT02100657

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇪🇸
Hospital Universitario Germans Trias I Pujol, Badalona, Barcelona, Spain
🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain

and more 4 locations

Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial

Phase 2

Terminated

Conditions: Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma

Interventions: Drug: plitidepsin

First Posted Date: 2013-06-12

Last Posted Date: 2021-01-25

Lead Sponsor: Institut Bergonié

Target Recruit Count: 24

Registration Number: NCT01876043

Locations: 🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Hôpital de la Timone, Marseille, France
🇫🇷
Centre Oscar Lambret, Lille, France

and more 3 locations

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Phase 3

Completed

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Plitidepsin
Drug: Dexamethasone

First Posted Date: 2010-04-13

Last Posted Date: 2020-11-10

Lead Sponsor: PharmaMar

Target Recruit Count: 255

Registration Number: NCT01102426

Locations: 🇬🇧
1003, Bournemouth, United Kingdom
🇦🇹
201, Wien, Austria
🇺🇸
1102, New York, New York, United States

and more 79 locations

A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-09-29

Last Posted Date: 2009-12-24

Lead Sponsor: PharmaMar

Target Recruit Count: 51

Registration Number: NCT00229203

Locations: 🇺🇸
Jerome Lipper Multiple Myeloma Center - Dept of Medical Oncology - Dana Farber Cancer Institute, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy